Recruiting
Study of Early versus Delayed Treatment with Azathioprine or Rituximab in Children with Anti-MOG Antibody Disease
Registered drugNo placebo
Study of Early versus Delayed Treatment with Azathioprine or Rituximab in Children with Anti-MOG Antibody Disease
Registered drugNo placebo
- Disease:Myelin oligodendrocyte glycoprotein antibody-associated disease
- Substances:AzathioprineMethylprednisolone+3
Countries:
France
France- Participants:0–17 years
- Substances:Azathioprine
- Sponsor:Assistance Publique Hopitaux De Paris
